{"entity":{"id":"nct01744223","kind":"trial","name":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","aka":[],"tldr":"A phase 1/2 trial of BPX-501 dose 1 in acute lymphoblastic leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting.","summary":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant is a phase 1/2 interventional study registered as NCT01744223 by Bellicum Pharmaceuticals, with 36 participants enrolled, started 2013-03 and due to reach its primary completion in 2019-10-09. Interventions recorded: BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4 and SCT.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01744223","url":"https://clinicaltrials.gov/study/NCT01744223"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia","non-hodgkin-lymphoma","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bellicum"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT01744223","phase":"1/2","setting":"A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)","sponsor":"Bellicum Pharmaceuticals","enrolled":36,"outcomes":[]},"route":"/trials/nct01744223/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/"}]}}